Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2004 for Biogen Idec Inc. The company operates as a global leader in the development, manufacturing, and commercialization of novel therapies in oncology, immunology, and neurobiology. The reporting period includes the full-year results of the merged entity following the November 2003 merger between IDEC Pharmaceuticals Corporation and Biogen, Inc.
The company's portfolio consists of five primary products: AVONEX (multiple sclerosis), RITUXAN (non-Hodgkin's lymphoma), ZEVALIN (non-Hodgkin's lymphoma), AMEVIVE (psoriasis), and TYSABRI (multiple sclerosis). A critical event occurring shortly after the reporting period was the voluntary suspension of TYSABRI marketing and clinical trials in February 2005 due to reports of progressive multifocal leukoencephalopathy (PML).
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Total Revenues | $2,211.6 million | $679.2 million |
| Net Income (Loss) | $25.1 million | ($875.1 million) |
| Diluted EPS | $0.07 | ($4.92) |
| Research & Development Expenses | $687.7 million | $233.3 million |
| Cash, Cash Equivalents & Marketable Securities | $2,167.6 million | $2,338.3 million |
| Total Assets | $9,165.8 million | $9,503.9 million |
| Notes Payable (Current + Long-term) | $850.3 million | $887.3 million |
Note: 2003 results include a one-time charge of $823.0 million for in-process research and development (IPR&D) related to the merger.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 226% to $2.21 billion, driven primarily by the inclusion of a full year of Biogen, Inc. operations (AVONEX and AMEVIVE) and increased RITUXAN copromotion profits.
- Profitability: The company returned to profitability with $25.1 million in net income, compared to a significant loss in 2003. The 2003 loss was heavily influenced by the $823 million IPR&D write-off and acquisition-related intangible amortization.
- Product Performance:
- AVONEX: Worldwide revenues reached $1.42 billion (up from $142.6 million in the partial 2003 period).
- RITUXAN: U.S. copromotion profits recorded by Biogen Idec increased to $469.5 million (up from $419.2 million).
- TYSABRI: Generated $3.1 million in revenue in late 2004 following FDA approval in November.
- Inventory Write-downs: The company recorded $46.7 million in inventory write-downs in 2004, including $19.1 million for TYSABRI inventory due to uncertainty regarding its future commercial availability following the PML reports.
Guidance, Outlook, Risks, and Unusual Items
- TYSABRI Suspension (Critical Risk): In February 2005, Biogen Idec and Elan voluntarily suspended the marketing and distribution of TYSABRI and halted clinical trials due to two cases of PML. A third case was identified in March 2005. The company expects to expense an additional $22–$25 million of TYSABRI inventory in Q1 2005 and is evaluating the potential for permanent withdrawal or restricted re-launch.
- Debt Obligations: The company faces a significant liquidity event in April 2005. Holders of senior notes due 2032 may require the company to repurchase approximately $753 million of notes. Management expects this repurchase to occur, requiring the liquidation of marketable securities.
- Manufacturing Facilities: The company is constructing large-scale facilities in Oceanside, California, and Hillerod, Denmark, primarily for TYSABRI. The future utility of these facilities is now contingent on the resolution of the TYSABRI safety issues. The company expects to write off $6.5 million in engineering costs for the Hillerod facility in Q1 2005.
- Legal Proceedings: Following the TYSABRI suspension, the company faces multiple class-action lawsuits and shareholder derivative actions alleging securities fraud and breach of fiduciary duty. The company also faces ongoing litigation regarding patent royalties (Columbia University) and Medicaid reimbursement practices.
- Outlook: Management anticipates higher R&D and SG&A expenses in 2005 due to TYSABRI evaluations and legal costs. Gross margins are expected to improve in 2005 as the impact of purchase accounting adjustments on inventory costs diminishes.
Key Facts for Investor Verification
- TYSABRI Safety Review Outcome: Verify the results of the safety database review and FDA/EMA decisions regarding the potential re-launch of TYSABRI, as this product was a major growth driver.
- Senior Note Repurchase: Confirm the execution and funding of the anticipated $753 million repurchase of senior notes in April 2005 and its impact on cash reserves.
- Inventory Valuation: Monitor Q1 2005 financials for the expected $22–$25 million TYSABRI inventory expense and the $6–$8 million AVONEX inventory write-down related to the new pre-filled syringe formulation.
- Legal Exposure: Track the status of the class-action lawsuits and SEC inquiry regarding the TYSABRI suspension and insider trading allegations.
- Manufacturing Capacity: Assess the long-term strategic value of the Oceanside and Hillerod manufacturing facilities if TYSABRI is permanently withdrawn or significantly restricted.